Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E T Creagan

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
American Journal of Clinical Oncology|June 1, 1986
Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAPR T Eagan, S Frytak, E T Creagan, et al.
Cancer Treatment Reports|May 1, 1987
Phase I study of two schedules of teroxironeJ Rubin, J S Kovach, M M Ames, et al.
Cancer|February 1, 1987
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysesE T Creagan, D L Ahmann, S Frytak, et al.
Cancer Treatment Reports|August 1, 1980
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lungR T Eagan, S Frytak, J N Ingle, et al.
Cancer Treatment Reports|May 1, 1981
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancersR T Eagan, S Frytak, W C Nichols, et al.
American Journal of Clinical Oncology|April 1, 1987
No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Cancer Treatment Reports|January 1, 1980
Phase II evaluation of AMSA in patients with metastatic lung cancerW C Nichols, R T Eagan, S Frytak, et al.
Cancer Clinical Trials|January 1, 1981
A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1985
Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanomaE T Creagan, D L Ahmann, S J Green, et al.
Mayo Clinic Proceedings|December 1, 1992
Locally recurrent non-small-cell lung cancer after complete surgical resectionE G Shaw, J S Brindle, E T Creagan, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
American Journal of Clinical Oncology|June 1, 1986
Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAPR T Eagan, S Frytak, E T Creagan, et al.
Cancer Treatment Reports|May 1, 1987
Phase I study of two schedules of teroxironeJ Rubin, J S Kovach, M M Ames, et al.
Cancer|February 1, 1987
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analysesE T Creagan, D L Ahmann, S Frytak, et al.
Cancer Treatment Reports|August 1, 1980
Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II) in patients with advanced adenocarcinoma of the lungR T Eagan, S Frytak, J N Ingle, et al.
Cancer Treatment Reports|May 1, 1981
Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancersR T Eagan, S Frytak, W C Nichols, et al.
American Journal of Clinical Oncology|April 1, 1987
No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Cancer Treatment Reports|January 1, 1980
Phase II evaluation of AMSA in patients with metastatic lung cancerW C Nichols, R T Eagan, S Frytak, et al.
Cancer Clinical Trials|January 1, 1981
A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1985
Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanomaE T Creagan, D L Ahmann, S J Green, et al.
Mayo Clinic Proceedings|December 1, 1992
Locally recurrent non-small-cell lung cancer after complete surgical resectionE G Shaw, J S Brindle, E T Creagan, et al.
Pageof 12